Bufexamac products for topical use: Revocation of authorisations in the EU because of unfavourable benefit-risk ratio
created: 2010.04.27
updated: 2010.04.27
Assessment of medicinal products containing bufexamac for topical use in the authorised indications has revealed a negative overall benefit-risk ratio. Therefore the authorisations are revoked
risk information - full text (available in German only)